Platform Development

About Aurora Therapeutics

Aurora Therapeutics was launched to solve the fundamental scalability problem in rare disease treatment, where over 350 million people worldwide lack therapies targeting their specific genetic mutations. The company is developing a platform that leverages CRISPR gene editing tools, which can be rapidly tailored to specific mutations with increasing precision, to create personalized treatments at scale. Led by CEO Edward M. Kaye and backed by investors like Menlo Ventures, Aurora is assembling a team of leaders in gene editing, rare-disease medicine, and therapeutic development to realize the potential of personalized gene editing for millions of patients.

Therapeutic Areas